The KEYS trial (2022) and INTERLACE trial (2024) both investigated modified treatment approaches for locally advanced cervical cancer. The INTERLACE trial showed that adding induction chemotherapy before chemoradiation resulted in:

• A No improvement in 5-year overall survival
• B Higher toxicity without survival benefit
• C Benefit only in stage IVA disease
• D Significant improvement in 5-year progression-free and overall survival ✓

Explanation

The INTERLACE trial (Lancet 2024) randomised locally advanced cervical cancer patients (Stage IB2–IVA) to induction chemotherapy (carboplatin-paclitaxel × 6 weeks) followed by standard chemoradiation vs chemoradiation alone. The induction arm showed significantly improved 5-year progression-free survival (73% vs 64%) and 5-year overall survival (80% vs 72%), establishing induction chemotherapy as a potential new standard in high-burden resource-adequate settings.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.